CCT7: A Potential Drug Target and Biomarker for T-Complex Protein 1 Subunit Eta (Isoform A)
CCT7: A Potential Drug Target and Biomarker for T-Complex Protein 1 Subunit Eta (Isoform A)
CCT7 (T-complex protein 1 subunit eta (isoform a)) is a protein that plays a crucial role in various cellular processes, including DNA replication, transcription, and chromatin regulation. It is a key component of the T-complex, which is a complex of DNA-binding proteins that play essential roles in the regulation of gene expression. CCT7 functions as a negative regulator of the T-complex, inhibiting the activity of the protein Sss1, which is essential for the recruitment of regulatory factors to DNA.
Recent studies have identified CCT7 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will provide an overview of CCT7, its functions, and potential as a drug target and biomarker.
Functions and Localization
CCT7 is a 21-kDa protein that is composed of 195 amino acid residues. It has a molecular weight of 21 kDa and a calculated pI of 9.97. CCT7 is predominantly localized to the nucleus, where it is predominantly composed of N- and C-termini. It also has a limited presence in the cytoplasm.
CCT7 is a key component of the T-complex, which is a complex of DNA-binding proteins that play essential roles in the regulation of gene expression. The T-complex is composed of several subunits, including Sss1, Sss2, and Sss3, which are involved in the recruitment of regulatory factors to DNA. Sss1 is the most well-studied subunit and is responsible for the recruitment of the protein p16, which is essential for the formation of the T-complex.
CCT7 functions as a negative regulator of the T-complex, inhibiting the activity of Sss1. This inhibition allows for the recruitment of regulatory factors to DNA and the regulation of gene expression. CCT7 has been shown to play a role in the regulation of gene expression in various organisms, including bacteria and yeast.
Potential as a Drug Target
CCT7 has been identified as a potential drug target due to its involvement in various cellular processes that are altered in various diseases. Its functions in the regulation of gene expression have led to the hypothesis that it may be a useful target for drugs that target the T-complex and prevent its dysfunction.
One of the main drug targets associated with CCT7 is the inhibition of Sss1, which is critical for the recruitment of regulatory factors to DNA. This can be achieved by inhibiting the activity of Sss1 using small molecules, such as inhibitors of tyrosine kinase, which are commonly used in drug development.
Another potential mechanism by which CCT7 can be targeted is its role in the regulation of DNA replication. CCT7 has been shown to play a role in regulating the DNA replication process in various organisms, including bacteria and yeast. Its dysfunction has been implicated in the development of certain cancers, including breast and ovarian cancers.
In addition to its potential as a drug target, CCT7 has also been identified as a potential biomarker for various diseases. Its involvement in the regulation of gene expression has led to the hypothesis that it may be a useful biomarker for diseases that are characterized by altered regulation of gene expression. For example, CCT7 has been shown to be overexpressed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
Potential as a Biomarker
CCT7 has also been identified as a potential biomarker for various diseases due to its involvement in the regulation
Protein Name: Chaperonin Containing TCP1 Subunit 7
Functions: Component of the chaperonin-containing T-complex (TRiC), a molecular chaperone complex that assists the folding of proteins upon ATP hydrolysis (PubMed:25467444). The TRiC complex mediates the folding of WRAP53/TCAB1, thereby regulating telomere maintenance (PubMed:25467444). The TRiC complex plays a role in the folding of actin and tubulin (Probable)
The "CCT7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCT7 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B
